59 results about "Immunologic Technique" patented technology

The invention provides a reagent for detecting avian leukosis virus, a nano-enzyme immunochromatography test strip and application of the nano-enzyme immunochromatography test strip, and belongs to the technical field of immunology. Aiming at the problems that the existing avian leukosis virus detection method is complicated in operation, time-consuming or strong in equipment dependence, the reagent comprises a capture antibody and a detection antibody; a heavy chain variable region of the monoclonal antibody A comprises an amino acid sequence as shown in SEQ ID NO: 1, and a light chain variable region of the monoclonal antibody A comprises an amino acid sequence as shown in SEQ ID NO: 2; a heavy chain variable region of the monoclonal antibody B comprises an amino acid sequence as shown in SEQ ID NO: 5, and a light chain variable region of the monoclonal antibody B comprises an amino acid sequence as shown in SEQ ID NO: 6; the antigen binding fragment is a Fab fragment, an F (ab) 2 fragment or a single-chain Fv fragment. The reagent is mainly used for detecting avian leukosis virus, and is suitable for detecting samples such as cloaca swab, meconium, egg white or serum of poultry.

The application belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting cross binding of human and cynomolgus monkey CD46 and application thereof. The application utilizes alpaca to generate nanoscale antibodies, the molecular weight of which is about 15 kDa, and the nanoscale antibodies can more efficiently penetrate solid tumor tissues or cross blood-brain barrier, and the binding efficiency of the antibodies and target points is as high as possible. The 11 single-domain antibodies prepared by the application have specificity of anti-human and anti-cynomolgus monkey CD46, and in the binding detection with CD46 target proteins and CD46 overexpression cells, the binding efficiency is significantly better than that of Anti-CD46 humanization antibody, and the single-domain antibodies can be used for tumor treatment. Meanwhile, the single-domain antibodies have cross binding ability of cross species, and can be directly used for preclinical pharmacodynamics and safety evaluation, without the need of developing species-specific alternative antibodies, so that the application achieves 'one target and double effect'.

The invention belongs to the technical field of immunology, and particularly relates to an anti-TNF-alpha nano antibody as well as a preparation method and application thereof. The anti-TNF-alpha nano antibody sequence with high affinity is obtained through four rounds of optimized phage screening, and further, the soluble expression quantity of the nano antibody is improved by utilizing a pET26a (+)-BL21 expression system and combining a codon optimization technology. The nano antibody can be used for preparing a reagent for treating or diagnosing TNF-alpha related diseases, and has extremely high practical application value.

The application provides an anti-IL-17A nanobody, a pharmaceutical composition, a method and a use, and belongs to the technical field of cellular immunology. The antibody provided by the application comprises a complementarity determining region HCDR, and the complementarity determining region HCDR comprises: (1) HCDR1 with an amino acid sequence as shown in SEQ ID NO:1, HCDR2 with an amino acid sequence as shown in SEQ ID NO:2, and HCDR3 with an amino acid sequence as shown in SEQ ID NO:3; and / or (2) an amino acid sequence with a sequence similarity of at least 80% with SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 respectively. The antibody has high affinity, strong blocking ability and stability, and the single-domain antibody has broad application prospects in the treatment of autoimmune diseases.

The invention belongs to the technical field of immunology, and discloses a manganese salt adjuvant system based on dextran particle capsule shrinkage and a preparation method and application thereof.The manganese salt adjuvant system comprises beta-dextran particles GPs of a hollow spherical shell structure from yeast and manganese hydroxide colloid encapsulated in the dextran particles, the preparation method comprises the following steps: soaking the GPs in a MnCl2 solution, after the inner cavity of the GPs fully absorbs the MnCl2 solution, separating the GPs adsorbing MnCl2, then adding the GPs into a NaOH solution, forming stable manganese hydroxide colloid by manganese ions in the inner cavity of the GPs, and washing after separation to obtain the dextran particle encapsulated manganese salt adjuvant system. The GPMnOH particles carry various antigens at the same time in various modes such as electrostatic adsorption, chemical coupling or hydrophobic interaction, and an ideal carrier is provided for co-delivery immunization of the antigens and adjuvants.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

The application discloses an anti-human TRPS1 monoclonal antibody and a preparation method and application thereof, and belongs to the technical field of immunology. The anti-human TRPS1 monoclonal antibody provided by the application comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences as shown in SEQ ID NO. 1-3, and VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences as shown in SEQ ID NO. 4-6. The nucleotide sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody, an expression cassette containing the nucleotide sequences, an expression vector, a recombinant cell and a recombinant bacterium are also provided. Therefore, the monoclonal antibody can be prepared by using genetic engineering technology, and the risk factors in the production and storage process of the traditional monoclonal antibody can be avoided. The monoclonal antibody prepared by the application has stable properties, high experimental repeatability and high titer, and has good specificity and affinity to the TRPS1 protein.

The application discloses a monoclonal antibody of SARS-CoV-2 N protein and a preparation method and application of a test strip thereof. The red microsphere immunochromatography test strip prepared from the monoclonal antibody of SARS-CoV-2 N protein can quickly and accurately detect SARS-CoV-2 N protein, shortens the detection time, simplifies the detection steps, has the characteristics of being quick and convenient and being suitable for on-site detection, and provides a reliable immunological technology for quickly and efficiently detecting SARS-CoV-2 infection.

The invention belongs to the technical field of biological medicine and immunology, and particularly relates to a single-domain antibody targeting PD-L1 cross binding of human and cynomolgus monkeys and application of the single-domain antibody. The single-domain antibody disclosed by the invention has the specificity of resisting PD-L1 of human and cynomolgus monkeys, and shows relatively strong binding efficacy in the binding detection of PD-L1 target protein or PD-L1 overexpression cells; in the detection of blocking PD-1 / PD-L1 functions, a part of the single-domain antibodies even show a blocking effect which is obviously superior to that of Atezolizumab, so that the single-domain antibodies prepared by the invention can be used for diagnosis, treatment and prognosis detection of PD-L1 positive tumors. Meanwhile, the single-domain antibody disclosed by the invention has cross-species cross binding capacity, can be directly used for preclinical pharmacodynamics and safety evaluation, does not need to develop a species-specific substitution antibody, and realizes'one target and double effects'.

The invention provides a fully humanized monoclonal antibody for resisting SARS-CoV and SARS-CoV-2 and application of the fully humanized monoclonal antibody, and belongs to the technical field of immunology, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO: 1; the amino acid sequence of a light chain variable region of the monoclonal antibody SARS2-1 is as shown in SEQ ID NO: 2; the antibody has a unique CDR partition, can identify S proteins of the two viruses at the same time, and has cross-neutralization activity on pseudoviruses of the two viruses. The antibody has the characteristics of high expression, full human source and good stability, is suitable for industrial production, and has potential application value for coping with outbreak prevalence caused by coronavirus possibly occurring at present and in the future.

The present application relates to the technical field of immunology, and particularly relates to a murine IgG monoclonal antibody, a preparation method and application thereof. The heavy chain variable region of the monoclonal antibody has an amino acid sequence as shown in SEQ ID NO:1; and the light chain variable region has an amino acid sequence as shown in SEQ ID NO:2. The present application further discloses a DNA molecule encoding the antibody, expression of the antibody, and a eukaryotic host cell transformed by the expression vector. The murine IgG monoclonal antibody provided by the present application is preliminarily verified in a 5L bioreactor, and the expression amount is 5.33g / L. It is identified that the monoclonal antibody is used as a blocking agent for evaluation, and the blocking effect is obvious, and plays an important role in the use of blocking agents.

The invention belongs to the technical field of immunology, and particularly relates to a mouse anti-siniperca chuatsi secretory immunoglobulin T monoclonal antibody as well as a preparation method and application thereof. The invention provides a hybridoma cell strain 6B7 capable of secreting an anti-siniperca chuatsi secretory immunoglobulin T (sIgT) monoclonal antibody or an antigen binding fragment thereof for the first time, the hybridoma cell strain 6B7 is preserved in China Center for Type Culture Collection on May 13, 2025, and the preservation number is CCTCC NO: C2025161. The anti-siniperca chuatsi IgT monoclonal antibody or the antigen binding fragment of the anti-siniperca chuatsi IgT monoclonal antibody can be subjected to specific reaction with siniperca chuatsi secreting type IgT protein, and can be applied to detection of IgT in a siniperca chuatsi serum sample.

The invention belongs to the technical field of immunology, and discloses an anti-human CD19 receptor single-domain antibody, and the amino acid sequence of the single-domain antibody is as shown in SEQ ID No.1. The antibody has good reaction activity with human CD19, can be used for detecting or diagnosing CD19 and treating related diseases with abnormal CD19 expression, and has wide application prospects in the fields of drug application, clinical detection and diagnosis and the like.

The invention belongs to the technical field of experimental animal models, biomedical research and immunology, and discloses a photocoagulation thymus ischemia animal model, a method and application of the photocoagulation thymus ischemia animal model in rapid simulation of thymus degeneration and immune senescence, and the model shows at least one or more characteristics 1-7 days after induction: thymus atrophy, thymus weight or thymus index is significantly reduced; the cortical-medullary structure of thymus is disordered or disappears; the expression distribution of the Keratin 5 / Keratin 8 is abnormal; thymic cell apoptosis is increased, and lipid deposition is enhanced; the proportion of CD4 + CD8 + double positive T cells is reduced, and the proportion of DN2 / DN3 stage T cells is increased; the initial T cell output is reduced; and the immune function is reduced. The pathological mechanism is clear; the modeling period is short, and the immune senescence phenotype can be stably obtained within several days; the injury focus is controllable, and systemic stress or hormone interference is avoided; the model has high repeatability and is suitable for mechanism research and drug screening.

The application provides a target RBD anti-Omicron fully human monoclonal antibody 9C4 and application thereof, and belongs to the technical field of microbiology and immunology. The monoclonal antibody 9C4 comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of three complementarity determining regions of the heavy chain variable region are GYAFTTYG, ISTYNGNT and ATSLGLWFGQNS respectively, and the amino acid sequences of three complementarity determining regions of the light chain variable region are SGSIASNY, EDN and QTYDGSNQV respectively. The monoclonal antibody 9C4 provided by the application has high-efficiency, specific anti-Omicron neutralization activity, is fully human, has good stability, and has great application potential in the preparation of a novel coronavirus detection product or a drug for preventing and treating a novel coronavirus disease.

This invention provides a fully human anti-H3N2 virus neutralizing antibody IAV-3 and its applications, belonging to the fields of microbiology and immunology. The amino acid sequence of the heavy chain variable region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:2; the amino acid sequence of the heavy chain constant region of the neutralizing antibody IAV-3 is shown in SEQ ID NO:3, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO:4. The neutralizing antibody provided by this invention has the characteristics of high expression, fully human origin, and good stability, making it suitable for industrial production and possessing potential application value in responding to current and future influenza caused by the H3N2 virus.

The invention relates to the technical field of molecular biology and immunology, in particular to a porcine epidemic diarrhea virus-like particle subunit vaccine and a preparation method thereof. The invention provides a porcine epidemic diarrhea virus-like particle subunit vaccine. The vaccine is formed by assembling partial fragments of porcine epidemic diarrhea PEDV S protein and virus-like particles. Compared with a traditional subunit vaccine, the porcine epidemic diarrhea virus-like particle vaccine has the advantages that the immune efficacy is greatly improved, compared with an inactivated vaccine, the porcine epidemic diarrhea virus-like particle vaccine has a better immune effect, has no pathogenicity to animals such as mice and the like, and can induce high-level neutralizing antibodies in animal bodies.

The invention discloses a CD147 nano antibody D2 as well as a preparation method and application thereof, and belongs to the technical field of molecular biology and immunology. The preparation method comprises the following steps: screening from an alpaca nano antibody phage library by utilizing a phage display technology, and sequencing to obtain 9 CD147 nano antibodies; 3 nano antibody genes are selected and cloned into pCold II, and prokaryotic expression recombinant plasmids are successfully constructed; the method comprises the following steps: carrying out inducible expression for 20 hours under the conditions that the final concentration of IPTG (isopropyl-beta-d-thiogalactoside) is 0.2 mmoL / L, the temperature is 16 DEG C and the speed is 100 rpm / min, carrying out nickel column purification, and then carrying out Coomassie brilliant blue dyeing and Western blot identification to determine and obtain the CD147 nano antibody which is named as C36, D2 and H4; the binding activity of the three nano antibodies and the CD147 protein is detected through indirect ELISA (enzyme-linked immuno sorbent assay). The result shows that the CD147 antigen and the three nano antibodies have binding activity and are dose-dependent. Under the same conditions, when the incubation concentration of the nano-antibody is as low as 1.25 micrograms / mL, the D2 binding effect is the best, the amino acid sequence of the nano-antibody is shown as SEQ ID NO.8, and the nucleotide sequence of the nano-antibody is shown as SEQ ID NO.10. The invention provides a more accurate method for detecting the CD147.

The invention discloses a CD147 nano antibody G45 as well as a preparation method and application thereof, and belongs to the technical field of molecular biology and immunology. A phage display technology is used for screening from a natural alpaca nano antibody phage library, finally three nano antibody genes are selected and cloned into pCold II, and prokaryotic expression recombinant plasmids are successfully constructed; the method comprises the following steps: carrying out inducible expression for 20 hours under the conditions that the final concentration of IPTG (isopropyl-beta-d-thiogalactoside) is 0.2 mmoL / L, the temperature is 16 DEG C and the speed is 100 rpm / min, carrying out nickel column purification, and then carrying out Coomassie brilliant blue dyeing and Western blot identification, so as to determine and obtain the CD147 nano antibody which is named as A8, B8 and G45; the binding activity of the three nano antibodies and the CD147 protein is detected through indirect ELISA (enzyme-linked immuno sorbent assay). The result shows that the CD147 antigen and the three nano antibodies have binding activity and are dose-dependent. Under the same conditions, when the incubation concentration of the nano-antibody is as low as about 0.625 g / mL, the G45 binding effect is good, the amino acid sequence of the nano-antibody is shown as SEQ ID NO.7, and the nucleotide sequence of the nano-antibody is shown as SEQ ID NO.10. The invention provides a more accurate method for high-sensitivity detection of CD147.

The application provides a target RBD anti-Omicron fully human monoclonal antibody 3G5 and an application thereof, and belongs to the technical field of microbiology and immunology. The monoclonal antibody 3G5 comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region has three complementary determining regions, and the amino acid sequences of the three complementary determining regions are GGS I SS SS NF, I YY SG ST and ARL DLGGDIVVPPAAKPYYYMDV respectively; the light chain variable region has three complementary determining regions, and the amino acid sequences of the three complementary determining regions are SSNIGAGYN, GDI and QSYDSSLSGLYV respectively. The monoclonal antibody 3G5 provided by the application has high-efficiency and specific anti-Omicron neutralization activity, is fully human and has good stability, and has great application potential in the preparation of a novel coronavirus detection product or a drug for preventing and treating a novel coronavirus disease.

The application provides an avian PCV3 gene and application thereof, and belongs to the technical field of animal virology and immunology. The application provides an avian PCV3 gene for the first time, which is named aPCV3, and the nucleotide sequence of the aPCV3 gene comprises any one of SEQ ID NO. 1-2 or a sequence with a homology of more than 90% with SEQ ID NO. 1 and 2. The virus strain containing the aPCV3 gene has a high virus titer and can be stably passaged for multiple times. The inactivated vaccine prepared from the virus strain containing the aPCV3 gene and the subunit vaccine prepared from the Cap gene or the Rep gene in the aPCV3 gene have a significant protective effect on poultry such as chickens, ducks and geese. The ELISA detection plate prepared from the Cap gene or the Rep gene in the aPCV3 gene can accurately detect PCV3 and has high specificity and repeatability.

The invention provides a chicken Marek's virus (MHC) II type molecule restriction epitope peptide, a gene, a primer group, a screening method and application, and belongs to the technical field of immunology. The restrictive epitope peptide of the II-type molecule BLB2 * 21 of the chicken Marek's virus MHC is obtained through AF3 structure prediction and screening, the deviation of traditional bioinformatics prediction is avoided, and the binding activity of the epitope peptide is guaranteed through accurate structure analysis and crystallization verification; the gene for coding the chicken Marek's virus MHC II type molecule restrictive epitope peptide can be used for preparing Marek's virus epitope vaccines and T cell activators, or can be used as a detection target for evaluating the immune state of chicken flocks, and technical support is provided for Marek's disease prevention and control, disease resistance breeding and novel vaccine research and development.

The invention discloses a gene for coding soluble VZV-gB-SpyTag protein and application of the gene, and belongs to the technical field of genetic engineering and immunology. The nucleotide sequence of the gene is as shown in SEQ ID NO. 8. The invention provides a gene for coding soluble VZV-gB-SpyTag as well as a recombinant plasmid and a recombinant microorganism thereof, soluble VZV-gB-SpyTag protein is prepared, Fe-gB nanoparticles are further constructed, the nanoparticles are uniform in size, good in dispersity and stable in structure, the cellular immune effect of the VZV-gB protein can be remarkably improved, and the VZV-gB-SpyTag protein can be used for preparing the soluble VZV-gB-SpyTag protein. The resistance of the body to varicella-zoster virus is enhanced. The invention provides technical support for prevention and treatment of varicella-zoster virus.

The invention relates to the technical field of cytobiology and immunology, and discloses a cell molecule activation method based on an aqueous two-phase system, which comprises the following steps: preparing the aqueous two-phase system with the concentration of 2-15wt%; adding a suspension containing target cell molecules into the aqueous two-phase system, performing centrifugal separation, and concentrating the target cell molecules; and adding an exogenous signal molecule into the concentrated target cell molecule to activate the target cell molecule. The method has a wide application prospect in the fields of cell therapy, regenerative medicine, tumor immunotherapy and the like. By rapidly activating and enhancing cell functions, the effect of cell therapy can be improved, and a new method is provided for personalized medical treatment and immunotherapy.

This invention discloses a PRRSV NADC30 lineage vaccine, its preparation method, and its applications, belonging to the field of immunology technology. The recombinant chimpanzee adenovirus vector is obtained by introducing the encoding gene of GP35 fusion protein or M-GP5 fusion protein into an expression vector; wherein, the GP35 fusion protein is constructed by linking GP3 and GP5 proteins with a flexible linker peptide; the M-GP5 fusion protein is constructed by linking M and GP5 proteins with a flexible linker peptide. The PRRSV NADC30 lineage vaccine of this invention achieves protection against PRRSV infection by inducing antigen-specific antibodies, neutralizing antibodies, Th1-type cellular immune responses, and / or lymphocyte proliferation reactions. This invention provides a promising candidate antigen and a highly efficient vaccine platform for developing novel recombinant chimpanzee adenovirus vector vaccines against currently circulating NADC30-like strains.

The application discloses an indirect ELISA kit for rapidly detecting porcine epidemic diarrhea virus IgA antibody and application thereof and belongs to the technical field of immunology. The application provides a recombinant PEDV-RBD protein, and an amino acid sequence of the recombinant PEDV-RBD protein is shown as SEQ ID NO. 3. The application constructs an indirect ELISA kit for detecting porcine epidemic diarrhea virus IgA antibody based on the recombinant PEDV-RBD protein, can accurately capture PEDV IgA antibody in sow milk or serum to realize detection, has the advantages of high sensitivity and strong specificity, and provides a technical means for prevention and control of porcine epidemic diarrhea.

This invention belongs to the fields of molecular virology and immunology, and provides an alpaca-derived nanobody that specifically binds to Chikungunya virus (CHIKV), its preparation method, and its applications. The nanobody has a heavy chain variable region (VHH), which comprises the following CDRs: CDR1 (amino acid sequence as shown in SEQ ID NO:1), CDR2 (amino acid sequence as shown in SEQ ID NO:2), and CDR3 (amino acid sequence as shown in SEQ ID NO:3). The VHH includes four frame regions FR1-FR4; FR1, FR2, FR3, and FR4 are arranged alternately with CDR1, CDR2, and CDR3 in sequence. The nanobody of this invention can efficiently neutralize CHIKV virus and inhibit its infection, and has the potential to prepare drugs or kits for the prevention, treatment, and / or detection of CHIKV infection. The nanobody of this invention can bind with high affinity to the E protein of CHIKV, effectively inhibiting CHIKV pseudovirus infection.

The invention relates to application of recombinant flagellin in preparation of an anti-Vibrio harveyi medicine for aquatic animals. Belongs to the technical field of bioengineering and immunology. The amino acid sequence of the recombinant flagellin is shown as SEQ ID No. 2; the nucleotide sequence of the gene of the recombinant flagellin is as shown in SEQ ID No. 1; the recombinant vector comprises an expression vector and a gene of the recombinant flagellin; the expression vector is a prokaryotic expression vector pET32a; the recombinant bacteria comprise host bacteria and the recombinant vector; and the host bacterium is a Rosetta engineering strain. After the vaccine prepared from the recombinant flagellin is injected into a fish body for 4 weeks and 8 weeks, the immune protection rates on vibrio harveyi are 61.12% and 47.83% respectively; after the vaccine prepared from the recombinant flagellin is injected into a fish body, the expression of a specific antibody can be remarkably improved; after the vaccine prepared from the recombinant flagellin is injected into a fish body, the enzyme activity of serum can be remarkably improved, and innate immune response and inflammation and cellular immune response are activated.

The invention discloses a novel anti-echinococcus monoclonal antibody, a hybridoma cell strain and application of the novel anti-echinococcus monoclonal antibody, and belongs to the technical field of biomedicine and immunology. The preservation number of the hybridoma cell strain Anti-Em-11 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 46598. According to the present invention, the specific monoclonal antibody is successfully prepared and identified, and Western blot and indirect immunofluorescence experiments prove that the obtained monoclonal antibody has high specificity on the recombinant protein. The invention lays a solid foundation for serological diagnosis of the echinococcosis and remarkably enriches the existing serological detection technical system.

The application discloses a multi-antigen epitope fusion protein of yak-derived B-type Pasteurella multocida, an outer membrane vesicle vaccine and a preparation method thereof, and relates to the technical fields of genetic engineering and immunology. The amino acid sequence of the multi-antigen epitope fusion protein is shown as SEQ ID NO. 2. The multi-antigen epitope fusion protein provided by the application can stimulate yak to produce specific antibodies and protect yak against yak-derived B-type Pasteurella multocida infection. Therefore, the multi-antigen epitope fusion protein provided by the application can be used to prepare a subunit vaccine for preventing yak-derived B-type Pasteurella multocida infection. The application further provides an outer membrane vesicle vaccine of yak-derived B-type Pasteurella multocida, which can effectively activate the humoral immune response of a test yak and produce high levels of specific antibodies, and thus can be applied to preventing yak-derived B-type Pasteurella multocida infection.